Letters, Statements & Analysis
AMCP communicates the importance of managed care pharmacy by collaborating with members to provide comments, analysis, and testimony to Congress and federal and state agencies on the impact of proposed regulations and laws on managed care pharmacy and patients.
AMCP submitted comments on a CMS proposed rule making changes to the Medicaid Drug Rebate Program to account for prescription drug value-based purchasing arrangements.
AMCP joined with other national pharmacy stakeholders to urge HHS to authorize pharmacists to order and administer COVID-19 vaccines when they become available.
AMCP joined with other health care stakeholders to urge Congressional leadership to bolster Medicaid funding due to the COVID-19 public health emergency.
AMCP joined with other associations to sign a second ASAE letter to Congress urging the inclusion of associations in COVID-19 business relief efforts.
CMS outlining proposed changes to the calculation of best price under the Medicaid Drug Rebate Program (MDRP), particularly how manufacturers should account for value-based purchasing programs.
On June 1, 2020, the FDA issued a RFI soliciting stakeholder input on the listing of patent information in the Orange Book, including on the types of patent currently listed and how changes to current patent listing practices may impact drug product development. Please send any feedback to advocacy@amcp.org by August 14, 2020.
On June 1, 2020, the FDA issued a RFI requesting stakeholder comments on updating and improving the Orange Book. Please send any feedback to advocacy@amcp.org by August 14, 2020.
AMCP joined with national pharmacy stakeholder organizations in issuing a statement of commitment to advocate against racial injustice and all forms of discrimination and to work to eliminate the resulting inequities in patient care.
AMCP submitted comments on CMS’s interim final rule making changes to the Medicare Advantage and Part D programs in response to the COVID-19 public health emergency focused on the provision of telehealth services to Medicare beneficiaries.
AMCP joined with organizations representing of America’s pharmaceutical supply and payment chain to release new policy principles promoting undisrupted patient access to medications during the COVID-19 pandemic.
The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare & Medicaid Services (CMS) for the opportunity to provide comments in response to its Information Collection Request titled “Medication Therapy Management Improvements – Standardized Format (CMS-10396)” published on February 18, 2020.
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to the FDA/Federal Trade Commission (FTC) Workshop on a Competitive Marketplace for Biosimilars, held on March 9, 2020.
